Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment

Basit Öğe Kaydı
dc.contributor.authorZhang, Ling
dc.contributor.authorPakmehr, Seyed Abbas
dc.contributor.authorShahhosseini, Reza
dc.contributor.authorHariri, Maryam
dc.contributor.authorFakhrioliaei, Azadeh
dc.contributor.authorShayan, Farid Karkon
dc.contributor.authorXiang, Wenxue
dc.contributor.authorShayan, Sepideh Karkon
dc.date.accessioned2023-12-18T08:50:46Z
dc.date.available2023-12-18T08:50:46Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi
dc.description.abstractImmunotherapies using immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy have achieved successful results against several types of human tumors, particularly hematological malignancies. However, their clinical results for the treatment of solid tumors remain poor and unsatisfactory. The immunosuppressive tumor microenvironment (TME) plays an important role by interfering with intratumoral T-cell infiltration, promoting effector T-cell exhaustion, upregulating inhibitory molecules, inducing hypoxia, and so on. Oncolytic viruses are an encouraging biocarrier that could be used in both natural and genetically engineered platforms to induce oncolysis in a targeted manner. Oncolytic virotherapy (OV) contributes to the reprogramming of the TME, thus synergizing the functional effects of current ICIs and CAR T-cell therapy to overcome resistant barriers in solid tumors. Here, we summarize the TME-related inhibitory factors affecting the therapeutic outcomes of ICIs and CAR T cells and discuss the potential of OV-based approaches to alleviate these barriers and improve future therapies for advanced solid tumors.
dc.identifier.citationZhang, L., Pakmehr, S. A., Shahhosseini, R., Hariri, M., Fakhrioliaei, A., Shayan, F. K. ... Shayan, S. K. (2024). Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment. Medical Oncology, 41(1). https://dx.doi.org/10.1007/s12032-023-02233-0
dc.identifier.doi10.1007/s12032-023-02233-0
dc.identifier.issn1357-0560
dc.identifier.issn1559-131X
dc.identifier.issue1
dc.identifier.pmid38062315
dc.identifier.scopus2-s2.0-85178958788
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://dx.doi.org/10.1007/s12032-023-02233-0
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12019
dc.identifier.volume41
dc.identifier.wos001116486500001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorShahhosseini, Reza
dc.language.isoen
dc.publisherHumana Press Inc.
dc.relation.ispartofMedical Oncologyen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectImmunotherapy
dc.subjectCAR T Cell
dc.subjectOncolytic Virotherapy
dc.subjectSolid Tumor
dc.subjectTumor Microenvironment
dc.titleOncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Shahhosseini-Reza-2024.pdf
Boyut:
838.53 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu